Citations

Clear

4796 citation(s) found for "Yu, Jennifer".

A tension offloading patch mitigates dermal fibrosis induced by pro-fibrotic skin injections
Wan, Derrick C. , Talbott, Heather E. , Griffin, Michelle , Mascharak, Shamik , Parker, Jennifer , Kuhnert, Maxwell M. , Guo, Jason , Deleon, Nestor Diaz, Lavin, Christopher V. , Abbas, Darren , Morgan, Annah , Valencia, C. Alexander , Cotterell, Asha C., Talbott, Heather E , Abbas, Darren , Guardino, Nicholas , Longaker, Michael T , desJardins-Park, Heather Elizabeth, Parker, Jennifer, Guo, Jason L. , Deleon, Nestor M. Diaz , Longaker, Michael T.

Mayo Clinic

No container title available | March 1, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3915097/v1 | PMID 38464040 Get It

Abstract Skin fibrosis is a clinical problem with devastating impacts but limited treatment options. In the setting of diabetes, insulin administration often causes local dermal fibrosis, leading to a range of clinical sequelae including impeded insulin absorption. Mechanical forces are important drivers of fibrosis and, clinically, physical tension offloading at the skin level using an elastomeric patch significantly reduces wound scarring. However, it is not known whether tension offloading could similarly prevent skin fibrosis in the setting of pro-fibrotic injections. Here, we develop a porcine model using repeated local injections of bleomycin to recapitulate key features of insulin-induced skin fibrosis. Using histologic, tissue ultrastructural, and biomechanical analyses, we show that application of a tension-offloading patch both prevents and rescues existing skin fibrosis from bleomycin injections. By applying single-cell transcriptomic analysis, we find that the fibrotic response to bleomycin involves shifts in myeloid cell dynamics from favoring putatively pro-regenerative to pro-fibrotic myeloid subtypes; in a mechanomodulatory in vitro platform, we show that these shifts are mechanically driven and reversed by exogenous IL4. Finally, using a human foreskin xenograft model, we show that IL4 treatment mitigates bleomycin-induced dermal fibrosis. Overall, this study highlights that skin tension offloading, using an FDA cleared, commercially available patch, could have significant potential clinical benefit for the millions of patients dependent on insulin.
Genetic correlations of alcohol consumption and alcohol use disorder with sex hormone levels in females and males
Waller, Cameron, Ho, Ada Man‐Choi , Batzler, Anthony , Geske, Jennifer R. , Ho, Ada, Geske, Jennifer, Winham, Stacey, Ho, Ada M-C , Geske, Jennifer , Karpyak, Victor M. , Biernacka, Joanna M. , Winham, Stacey J.

Mayo Clinic

No container title available | February 28, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3944066/v1 | PMID 38464231 Get It

Abstract Background Alcohol consumption behaviors and alcohol use disorder risk and presentation differ by sex, and these complex traits are associated with blood concentrations of the steroid sex hormones, testosterone and estradiol, and their regulatory binding proteins, sex hormone binding globulin (SHBG) and albumin. Genetic variation is associated with alcohol consumption and alcohol use disorder, as well as levels of steroid sex hormones and their binding proteins. Methods To assess the contribution of genetic factors to previously described phenotypic associations between alcohol-use traits and sex-hormone levels, we estimated genetic correlations (rg) using summary statistics from prior published, large sample size genome-wide association studies (GWAS) of alcohol consumption, alcohol dependence, testosterone, estradiol, SHBG, and albumin. Results For alcohol consumption, we observed positive genetic correlation (i.e. genetic effects in the same direction) with total testosterone in males (rg = 0.084, p = 0.007) and trends toward positive genetic correlation with bioavailable testosterone (rg = 0.060, p = 0.084) and SHBG in males (rg = 0.056, p = 0.086) and with albumin in a sex-combined cohort (rg = 0.082, p = 0.015); however in females, we observed positive genetic correlation with SHBG (rg = 0.089, p = 0.004) and a trend toward negative genetic correlation (i.e. genetic effects in opposite directions) with bioavailable testosterone (rg = -0.064, p = 0.032). For alcohol dependence, we observed a trend toward negative genetic correlation with total testosterone in females (rg = -0.106, p = 0.024) and positive genetic correlation with BMI-adjusted SHBG in males (rg = 0.119, p = 0.017). Several of these genetic correlations differed between females and males and were not in the same direction as the corresponding phenotypic associations. Conclusions Findings suggest that shared genetic effects may contribute to positive associations of alcohol consumption with albumin in both sexes, as well as positive associations between alcohol consumption and bioavailable testosterone and between alcohol dependence and SHBG in males. However, relative contributions of heritable and environmental factors to associations between alcohol-use traits and sex-hormone levels may differ by sex, with genetic factors contributing more in males and environmental factors contributing more in females.
Primary Pulmonary Myxoid Sarcoma and Thoracic Angiomatoid Fibrous Histiocytoma
Kerper, Allison L. , Larsen, Brandon T. , Folpe, Andrew L. , Roden, Anja C. , Torres‐Mora, Jorge , Aubry, Marie‐Christine, Kerper, Allison , Boland, Jennifer M. , Lo, Ying‐Chun , Aubry, Marie-Christine

Mayo Clinic

American Journal of Surgical Pathology | February 26, 2024 | Volume: 48 | Issue: 5 | Pages: 562-569

10.1097/pas.0000000000002189 | PMID 38407279 Get It

Primary pulmonary myxoid sarcoma (PPMS) and thoracic angiomatoid fibrous histiocytoma (AFH) are rare neoplasms with EWSR1 fusions and overlapping morphology. Both tumor types often show epithelial membrane antigen expression, but AFH characteristically co-expresses desmin. We encountered a case of PPMS with the unexpected finding of patchy, strong anaplastic lymphoma kinase (ALK) (previously reported in AFH) and synaptophysin expression. We evaluated a cohort of PPMS and thoracic AFH with systematic morphologic comparison and surveyed for aberrant expression of ALK and synaptophysin. Medical records and slides were reviewed for 16 molecularly confirmed cases of PPMS (n=5) and thoracic AFH (n=11). Each case was scored for morphologic characteristics typical of PPMS and/or AFH. ALK, synaptophysin, chromogranin, desmin, and epithelial membrane antigen immunostains were performed on cases with available tissue. AFH and PPMS cases showed similar age at presentation and long-term tumor behavior. Almost all cases of PPMS and AFH had a fibrous pseudocapsule and lymphoid rim. All PPMS had myxoid stroma and reticular growth pattern, but these features were also present in a subset of AFH. Synaptophysin expression was present in 6 of 11 AFH and 1 of 5 PPMS; all tested cases were negative for chromogranin (n=15). One case of AFH and 1 case of PPMS showed focally strong coexpression of synaptophysin and ALK. AFH and PPMS show considerable clinicopathologic overlap. When supportive, the immunohistochemical findings described may aid in diagnosis before molecular confirmation. PPMS and AFH may be morphologic variants of the same clinicopathologic entity, which can show more immunophenotypic variability than previously reported.
Lens and solution properties in patients with and without midday fogging
Fogt, Jennifer Swingle , Nau, Cherie B. , Harthan, Jennifer , Nau, Amy , Patton, Kim, Schornack, Muriel , Nau, Cherie, Schornack, Muriel , Fogt, Jennifer Swingle , Shorter, Ellen , Patton, Kimberly

Mayo Clinic

Ophthalmic and Physiological Optics | February 26, 2024 | Volume: 44 | Issue: 4 | Pages: 769-773

10.1111/opo.13293 | PMID 38404141 Get It

Abstract Introduction Midday fogging is a complication of scleral lens (SL) wear that interrupts clear vision during the course of wear. SLs can be made with a variety of gas permeable materials, sizes and surface treatments, and various solutions are available for storing the lenses and for filling them before application on the eye. Many of these factors have been implicated as possible contributors to midday fogging. This study explored the lens and solution properties in habitual SL wearers with and without midday fogging. Methods In this prospective study, 48 habitual SL wearers were evaluated and asked to report whether they experienced midday fogging and if they removed their lenses during the day. They completed the Ocular Surface Disease Index (OSDI), which is a validated tool for dry eye assessment. Lens parameters (material, coatings and diameter) and lens storage and filling solutions were documented. Backward elimination of regression terms evaluated the lens and solution properties in those with and without fogging. OSDI scores were compared using the Mann–Whitney analysis. Results Collectively, the lens properties and solutions accounted for 27.7% of the variance related to midday fogging. None of the factors alone had a significant impact upon midday fogging. The median (interquartile range) OSDI score for those with fogging [37 (35)] was significantly different from those without fogging [10 (15)], with the scores corresponding to severe dry eye and normal eyes, respectively. Conclusion SL wearers with midday fogging exhibited similar symptoms to patients with severe dry eye. Lens and solution characteristics may play a small role in patients with midday fogging, although changing just a single factor is not likely to impact its presence.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Jonasch, Eric, Alva, Ajjai , Bagshaw, H.P. , Costello, Brian A. , Derweesh, Ithaar , Desai, Arpita, Ged, Yasser , Johnson, Michael P. , King, Jennifer , Kyriakopoulos, Christos E. , Lara, Primo N. , Lau, Clayton, Lewis, Bryan , Mortazavi, Amir , Ponsky, Lee , Ramalingam, Sundhar, Shuch, Brian , Smith, Zachary L. , Sosman, Jeffrey A. , Zibelman, Matthew R. , Schonfeld, Ryan, Stein, MaryElizabeth , Gurski, Lisa A., Motzer, Robert J. , Agarwal, Neeraj , Baine, Michael J. , Beckermann, Kathryn E. , Carlo, Maria I. , Choueiri, Toni K. , George, Saby , Gore, John L. , Gunn, Andrew, Haas, Naomi B , Johnson, Michael, Kapur, Payal , King, Jennifer, Lam, Elaine T. , Madoff, David C. , Manley, Brandon J. , Michaelson, M. Dror , Sweis, Randy F.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 23, 2024 | Volume: 22 | Issue: 1 | Pages: 4-16

10.6004/jnccn.2024.0008 | PMID 38394781 Get It

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic therapy options for patients with advanced RCC and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Kidney Cancer.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shah, Neil P. , Bhatia, Ravi , Altman, Jessica K. , Amaya, Maria L. , Begna, Kebede H. , Berman, Ellin , Clements, Joan , Collins, Robert H. , Curtin, Peter , Drazer, Michael W. , Maness, Lori J., Metheny, Leland , Moore, Joseph O., Oehler, Vivian G. , Pratz, Keith W. , Pusic, Iskra , Rose, Michal G., Shomali, William , Styler, Michael , Tanaka, Tiffany , Tantravahi, Srinivas K. , Thompson, James E. , Tsai, Steven , Vaughn, Jennifer E. , Welborn, Jeanna, Yang, David T. , Sundar, Hema, Gregory, Kristina M., Drazer, Michael , Bhatia, Ravi , Chan, Onyee , DeAngelo, Daniel J. , Mohan, Sanjay , Smith, B. Douglas , Talpaz, Moshe , Amaya, Maria

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 23, 2024 | Volume: 22 | Issue: 1 | Pages: 43-69

10.6004/jnccn.2024.0007 | PMID 38394770 Get It

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase–CML. The primary goal of TKI therapy in patients with chronic phase–CML is to prevent disease progression to accelerated phase–CML or blast phase–CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase–CML.
Digitally Enabled Transitional Care Management in Oncology
Daly, Bobby , Cracchiolo, Jennifer R. , Holland, Jessie C. , Ebstein, Ann M. Mazzella , Flynn, Jessica , Duck, Elaine, Moy, Morgan, Walters, Chasity Burrows , Giacomazzo, Lisa, Huang, Jennie , Fahy, Rosanna Fiorarancio, Bernal, Camila , Ackerman, Jill , Salvaggio, Rori , Begue, Aaron , Raj, Nitya , Mao, Jun J. , Panageas, Katherine S. , Ebstein, AnnMarie Mazzella , Walters, Chasity B , Fahy, Rosanna, Kuperman, Gilad , Mao, Jun J

Mayo Clinic

JCO Oncology Practice | February 21, 2024 | Volume: 20 | Issue: 5 | Pages: 657-665

10.1200/op.23.00565 | PMID 38382002 Get It

PURPOSE Improving care transitions for patients with cancer discharged from the hospital is considered an important component of quality care. Digital monitoring has the potential to better the delivery of transitional care through improved patient-provider communication and enhanced symptom management. However, remote patient monitoring (RPM) interventions have not been widely implemented for oncology patients after discharge, an innovative setting in which to apply this technology. METHODS We implemented a RPM intervention which identifies medical oncology patients at discharge, monitors their symptoms for 10 days, and intervenes as necessary to manage symptoms. We evaluated the feasibility (>50% patient engagement with symptom assessment), appropriateness (symptom alerts), and acceptability (net promoter score >0.7) of the intervention and the initial effect on acute care visits and return on investment. RESULTS During the study period, January 1, 2021, to December 31, 2022, we evaluated 2,257 medical oncology discharges representing 1,857 unique patients. We found that 65.9% of patients discharged (N = 1,489) completed at least one symptom assessment postdischarge and of them, 45.5% (n = 678) generated a severe symptom alert that we helped to manage. Patients expressed high satisfaction with the intervention with a net promoter score of 84%. In preliminary analysis of patients with GI malignancies (n = 449), we found a nonsignificant decrease in 30-day readmissions for the intervention cohort (n = 269) by 5.8% as compared with the control (n = 180; from 33.3% to 27.5%; P = .22). CONCLUSION Digital transitional care management was feasible and demonstrated that patients transitioning from the hospital to home have a substantial symptom burden. The intervention was associated with high patient satisfaction but will require further refinement and evaluation to increase its impact on 30-day readmission.
Carbon Ion Radiotherapy: An Evidence-Based Review and Summary Recommendations of Clinical Outcomes for Skull-Base Chordomas and Chondrosarcomas
Seidensaal, Katharina , Iannalfi, Alberto , Koto, Masashi , Yang, Wan-Chin, Mahajan, Anita , Peterson, Jennifer , Koffler, Daniel , Vallow, Laura A., Rutenberg, Michael S. , Holtzman, Adam L. , Kim, Kyung Hwan , Ahmed, Safia K. , Trifiletti, Daniel M. , Hoppe, Bradford S.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1780150 Get It

Genome-wide association study identifies high-impact susceptibility loci for HCC in North America
Hassan, Manal M. , Li, Donghui , Han, Younghun , Choi, Jiyeon , Kelley, Robin Kate , Bracci, Paige M. , Bucur, Roxana , Ghobrial, R. Mark , Santella, Regina M. , Nguyen, Mindie H. , Liu, Geoffrey , Parikh, Neehar D. , Wu, Hui‐Chen , El‐Serag, Hashem B. , Chang, Ping , Li, Yanan , Chun, Yun Shin , Lee, Sunyoung S. , Gu, Jian , Hawk, Ernest T. , Huff, Chad , Rashid, Asif , Amin, Hesham M. , Beretta, Laura , Wolff, Robert A. , Antwi, Samuel O. , Patt, Yehuda Z., Hwang, Lu‐Yu, Schmidt, Mikayla A. , White, Donna L. , Goss, John A. , Khaderi, Saira, Marrero, Jorge A. , Cigarroa, Francisco , Roberts, Lewis R. , Han, Younghun , Roberts, Lewis R , Antwi, Samuel O , Liu, Geoffrey , Parikh, Neehar D , Beretta, Laura , Gu, Jian , Byun, Jinyoung , Hatia, Rikita , Long, Erping , Cleary, Sean P. , Lok, Anna S. , Permuth, Jennifer B. , Yuan, Jian-Min , Singal, Amit G. , Jalal, Prasun K. , Kono, Yuko , Shah, Dimpy P. , Nguyen, Mindie H. , Kim, Richard D. , Li, Yanan, Sun, Ryan , Klein, Alison P. , Zhang, Karen , Shah, Pankil , Kaseb, Ahmed O , Amos, Christopher I.

Mayo Clinic

Hepatology | February 21, 2024 | Volume: 80 | Issue: 1 | Pages: 87-101

10.1097/hep.0000000000000800 | PMID 38381705 Get It

Background and Aims: Despite the substantial impact of environmental factors, individuals with a family history of liver cancer have an increased risk for HCC. However, genetic factors have not been studied systematically by genome-wide approaches in large numbers of individuals from European descent populations (EDP). Approach and Results: We conducted a 2-stage genome-wide association study (GWAS) on HCC not affected by HBV infections. A total of 1872 HCC cases and 2907 controls were included in the discovery stage, and 1200 HCC cases and 1832 controls in the validation. We analyzed the discovery and validation samples separately and then conducted a meta-analysis. All analyses were conducted in the presence and absence of HCV. The liability-scale heritability was 24.4% for overall HCC. Five regions with significant ORs (95% CI) were identified for nonviral HCC: 3p22.1, MOBP, rs9842969, (0.51, [0.40–0.65]); 5p15.33, TERT, rs2242652, (0.70, (0.62–0.79]); 19q13.11, TM6SF2, rs58542926, (1.49, [1.29–1.72]); 19p13.11 MAU2, rs58489806, (1.53, (1.33–1.75]); and 22q13.31, PNPLA3, rs738409, (1.66, [1.51–1.83]). One region was identified for HCV-induced HCC: 6p21.31, human leukocyte antigen DQ beta 1, rs9275224, (0.79, [0.74–0.84]). A combination of homozygous variants of PNPLA3 and TERT showing a 6.5-fold higher risk for nonviral-related HCC compared to individuals lacking these genotypes. This observation suggests that gene-gene interactions may identify individuals at elevated risk for developing HCC. Conclusions: Our GWAS highlights novel genetic susceptibility of nonviral HCC among European descent populations from North America with substantial heritability. Selected genetic influences were observed for HCV-positive HCC. Our findings indicate the importance of genetic susceptibility to HCC development.
Correction: Adema et al. Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis. Pathogens 2023, 12, 703
Adema, Jennifer L. , Ahiskali, Aileen , Hornback, Krutika Mediwala , Rivera, Christina G. , Mediwala Hornback, Krutika , Rivera, Christina G , Fida, Madiha , Stevens, Ryan W.

Mayo Clinic

Pathogens | February 21, 2024 | Volume: 13 | Issue: 3 | Pages: 190

10.3390/pathogens13030190 | PMID 38535615 Get It

There was an error in the original publication [...]